Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Exeter IBD
Editorial: LAMP Lights the Way—A Pragmatic Case for NUDT15 Screening Across Diverse Populations—Authors' Reply
We thank Drs. Shah and Desai for their editorial [1] discussing our study [2]. Translation of pharmacogenetic biomarkers to the clinic is complex. The burden on central laboratories of testing and the cost of current methods mandates evidence of cost-effectiveness. Critically, data on variant allele penetrance and expressivity cannot be derived from classical gene discovery studies because of recall bias inherent to phenotype-first designs.
Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study
Research in context Evidence before this study The patient, disease, and pharmacokinetic factors implicated in anti-TNF treatment failure and loss of response remain poorly elucidated, in particular over the longer term.
Editorial: missed opportunities to detect colorectal cancer in inflammatory bowel disease-getting to the root. Authors’ reply
INVITED EDITORIAL PDF ShareShare Abstract LINKED CONTENT This article is linked to Gordon et al and Mahmoud & Itzkowitz papers.
Editorial: is pharmacogenetic testing for adverse effects to IBD treatments ready for roll‐out?
INVITED EDITORIAL Tariq Ahmad Corresponding Author E-mail address: tariq.ahmad1@nhs.net https://orcid.org/0000-0002-6058-5528 Exeter IBD and Pharmacogenetics Research Group, Exeter, UK Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK Search for more papers by this author Pharmacogenetics is the often‐hyped prototype of precision medicine.
Quality improvement project identifies factors associated with delay in IBD diagnosis
1 INTRODUCTION Delay in the diagnosis of inflammatory bowel disease (IBD), in particular Crohn's disease, is common.
HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn’s Disease
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Abstract Background & Aims Anti-tumor necrosis factor (anti-TNF) therapies are the most widely used biologic drugs for treating immune-mediated diseases, but repeated administration can induce the formation of anti-drug antibodies.
HLA-DQA1*05 is associated with the development of antibodies to anti-TNF therapy
HLA-DQA1*05 is associated with the development of antibodies to anti-TNF therapy Aleksejs Sazonovs, Nick Kennedy, Loukas Moutsianas, Graham A. Heap, Daniel L. Rice, Mark Reppell, Claire Bewshea, Gareth Walker, Mandy Perry, Timothy J. McDonald, Charlie Lees, Fraser Cummings, Miles Parkes, John Mansfield, Jeffrey C. Barrett, Dermot McGovern, James Goodhand, Carl A. Anderson, Tariq Ahmad, PANTS consortium bioRxiv 410035; doi: https://doi.org/10.1101/410035
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Exeter
Contact Exeter, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack